General Information of Drug (ID: DMEPQI4)

Drug Name
AZD4041 Drug Info
Indication
Disease Entry ICD 11 Status REF
Opioid use disorder 6C43.2Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMEPQI4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SB-649868 DMYLBOU Insomnia 7A00-7A0Z Phase 2 [3]
JNJ-61393215 DME2S4D Major depressive disorder 6A70.3 Phase 2 [4]
1,2-diamino cyclopentane-based derivative 25 DMEW0AT N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 5 DMCP15K N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 20 DM9PHIK N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 15 DMBY65W N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 13 DM10UX4 N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 9 DM7I8ZV N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 8 DM7JX8U N. A. N. A. Patented [5]
1,2-diamino cyclopentane-based derivative 26 DMTFG4J N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Orexin receptor type 1 (HCRTR1) TT60Q8D OX1R_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT05587998) A Randomized, Double-blind, Placebo-controlled, Fixed Sequence Study to Assess the Effect on Respiratory Drive of Multiple Doses of AZD4041 When Co-administered With a Single Dose of Morphine in Healthy Recreational Opioid Users. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
5 Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.